Overview

Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)

Status:
Recruiting

Trial end date:
2030-04-03

Target enrollment:

Participant gender:

Summary

Substudy 02B is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study. The goal of substudy 02B is to evaluate the safety and efficacy of investigational treatment arms in participants with 1L advanced melanoma and to identify the investigational agent(s) that, when used in combination, are superior to the current treatment options/pembrolizumab monotherapy.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.

Treatments:

Lenvatinib
Pembrolizumab